Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs

Journal of Nuclear Medicine Technology

Volumn 37, Issue 1, 2009, Pages 45-52

  Bryan, Jeffrey N ^a,c   Bommarito, David ^a   Kim, Dae Young ^b   Berent, Linda M ^b   Bryan, Margaret E ^c   Lattimer, Jimmy C ^a   Henry, Carolyn J ^a,d   Engelbrecht, Hendrik ^a   Ketring, Alan ^a   Cutler, Cathy ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

^d University of Missouri   (United States)

Author keywords

177lu dotmp; Bone tumors; Bone seeking radiopharmaceuticals; Dogs

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHATE LU 177; ETHYLENEDIAMINE TETRAMETHYLENE PHOSPHORIC ACID SM 153; LEXIDRONAM SAMARIUM SM 153; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; BONE CANCER; BONE LESION; BONE MARROW; BONE TUMOR; CHEMICAL ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOG; ERYTHROCYTE COUNT; EVALUATION; FEMALE; HALF LIFE TIME; LEUKOCYTE COUNT; MALE; METASTASIS; MICROSCOPY; NONHUMAN; THROMBOCYTE COUNT;

ANIMALS; BLOOD CELL COUNT; BONE MARROW; BONE NEOPLASMS; DOGS; FEMALE; LUTETIUM; MALE; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; RADIATION DOSAGE; RADIOISOTOPES; SAMARIUM;

EID: 62549141442     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnmt.108.054700     Document Type: Article

References (20)

1. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33:1451-1458.
2. Lattimer JC, Corwin LA Jr, Stapleton J, et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153- EDTMP. J Nucl Med. 1990;31:1316-1325.
3. Milner RJ, Dormehl I, Louw WK, Croft S. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours. J S Afr Vet Assoc. 1998;69:12-17.
4. Barnard SM, Zuber RM, Moore AS. Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005). J Am Vet Med Assoc. 2007;230:1877-1881.
5. Henry CJ, Lattimer JC, Milner RJ, et al. Hematological impact of administering samarium-153-EDTMP with or without concurrent carboplatin to dogs with appendicular osteosarcoma. In: 2007 Annual Proceedings of the Veterinary Cancer Society. Spring Valley, CA: Veterinary Cancer Society; 2007:56.
6. 177Lu-DOTMP: a new alternative to metastatic bone pain palliation/formulation studies. J Labelled Comp Radio-pharm. 2007;50(suppl):s276.
7. 177Lu- labeled DOTMPand EDTMP. J Labelled Comp Radiopharm. 2007;50(suppl):s446.
8. 177Lu-labeled cyclic polyaminophos-phonates as potential agents for bone pain palliation. Appl Radiat Isot. 2002; 57:177-184.
9. Volkert WA, Simon J, Ketring AR, Holmes RA, Lattimer JC, Corwin LA Jr. Radiolabeled phosphonic acid chelates: potential therapeutic agents for treatment of skeletal metastases. Drugs Future. 1989;14:799-811.
10. 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. Appl Radiat Isot. 2008;66:1196-1205.
11. Hansen K, Khanna C. Spontaneous and genetically engineered animal models: use in preclinical cancer drug development. Eur J Cancer. 2004;40:858-880.
12. Lattimer JC, Corwin LA Jr, Stapleton J, et al. Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. J Nucl Med. 1990;31:586-593.
13. Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol. 2005;131: 60-66.
14. Logan KW, Volkert WA, Holmes RA. Radiation dose calculations in persons receiving injection of samarium-153 EDTMP. J Nucl Med. 1987;28:505-509.
15. 153Sm-EDTMP in a canine. Appl Radiat Isot. 2005;63:79-85.
16. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med. 1994;35:63-69.
17. Littell RC, Henry PR, Ammerman CB. Statistical analysis of repeated measures data using SAS procedures. J Anim Sci. 1998;76:1216-1231.
18. Martin-Jiménez T, De Lorimier LP, Fan TM, Freise KJ. Pharmacokinetics and pharmacodynamics of a single dose of zoledronate in healthy dogs. J Vet Pharmacol Ther. 2007;30:492-495.
19. Skov KA. Radioresponsiveness at low doses: hyper-radiosensitivity and increased radioresistance in mammalian cells. Mutat Res. 1999;430:241-253.
20. Sawant SG, Randers-Pehrson G, Metting NF, Hall EJ. Adaptive response and the bystander effect induced by radiation in C3H 10T(1/2) cells in culture. Radiat Res. 2001;156:177-180.